PE20221568A1 - Compuestos de bencimidazol para el tratamiento de trastornos metabolicos - Google Patents

Compuestos de bencimidazol para el tratamiento de trastornos metabolicos

Info

Publication number
PE20221568A1
PE20221568A1 PE2022001524A PE2022001524A PE20221568A1 PE 20221568 A1 PE20221568 A1 PE 20221568A1 PE 2022001524 A PE2022001524 A PE 2022001524A PE 2022001524 A PE2022001524 A PE 2022001524A PE 20221568 A1 PE20221568 A1 PE 20221568A1
Authority
PE
Peru
Prior art keywords
treatment
metabolic disorders
compound
benzimidazole compounds
formula
Prior art date
Application number
PE2022001524A
Other languages
English (en)
Inventor
Azevedo Hatylas Felype Zaneti De
Junior Marcos Antonio Ferreira
Natanael Dante Segretti
Alessandra Mascarello
Cristiano Ruch Werneck Guimarães
Original Assignee
Ache Laboratorios Farmaceuticos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos Sa filed Critical Ache Laboratorios Farmaceuticos Sa
Publication of PE20221568A1 publication Critical patent/PE20221568A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a un compuesto de bencimidazol de formula I, o sales y cristales farmaceuticamente aceptables del mismo. Tambien se refiere a una composicion farmaceutica que comprende 0,01 a 5000 mg del compuesto de formula I. Dicho compuesto es un agonista melatonergico con mayor potencia en el receptor de melatonina MT1, siendo util en el tratamiento de obesidad, diabetes, enfermedad de higado graso no alcoholico y esteatohepatitis no alcoholica.
PE2022001524A 2020-04-15 2021-04-15 Compuestos de bencimidazol para el tratamiento de trastornos metabolicos PE20221568A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063010128P 2020-04-15 2020-04-15
PCT/BR2021/050158 WO2021207816A1 (en) 2020-04-15 2021-04-15 Benzimidazole compound for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
PE20221568A1 true PE20221568A1 (es) 2022-10-06

Family

ID=78083461

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001524A PE20221568A1 (es) 2020-04-15 2021-04-15 Compuestos de bencimidazol para el tratamiento de trastornos metabolicos

Country Status (15)

Country Link
US (1) US20230128304A1 (es)
EP (1) EP4136079A4 (es)
JP (1) JP2023522062A (es)
KR (1) KR20230002427A (es)
CN (1) CN115335363A (es)
AR (1) AR121842A1 (es)
AU (1) AU2021256476A1 (es)
CA (1) CA3171746A1 (es)
CL (1) CL2022002821A1 (es)
CO (1) CO2022012616A2 (es)
EC (1) ECSP22078679A (es)
GB (1) GB2609793B (es)
MX (1) MX2022009872A (es)
PE (1) PE20221568A1 (es)
WO (1) WO2021207816A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
AU2003902860A0 (en) * 2003-06-06 2003-06-26 Daicel Chemical Industries, Ltd Benzimidazole compounds
ES2331274B1 (es) * 2007-10-25 2010-10-21 Ferrer Internacional, S.A. Compuesto de indolina.
MX2011003239A (es) * 2008-09-26 2011-04-28 Merck Sharp & Dohme Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos.
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
ES2711808B2 (es) * 2017-11-02 2020-03-13 Univ Granada Uso de un agonista de melatonina para inducir la para inducir adipocitos beige en el tejido adiposo blanco

Also Published As

Publication number Publication date
MX2022009872A (es) 2022-08-22
GB202215434D0 (en) 2022-11-30
AU2021256476A1 (en) 2022-08-25
AR121842A1 (es) 2022-07-13
CN115335363A (zh) 2022-11-11
WO2021207816A1 (en) 2021-10-21
CA3171746A1 (en) 2021-10-21
ECSP22078679A (es) 2022-11-30
GB2609793A (en) 2023-02-15
CL2022002821A1 (es) 2023-04-10
EP4136079A4 (en) 2024-05-15
JP2023522062A (ja) 2023-05-26
US20230128304A1 (en) 2023-04-27
GB2609793A8 (en) 2023-03-22
CO2022012616A2 (es) 2022-10-21
GB2609793B (en) 2024-05-08
KR20230002427A (ko) 2023-01-05
EP4136079A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
AR070731A1 (es) Composicion farmaceutica para farmacos poco solubles
PE20081878A1 (es) Compuestos derivados de 1-(4-hidroxifenil sustituido)-4-ol-indazol
CO6270360A2 (es) Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos
AR040682A1 (es) Forma de dosificacion una vez al dia de pramipexol
SV2011003912A (es) Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1
MA30142B1 (fr) Agonistes du recepteur de neuropeptide-2
AR066882A1 (es) Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato.
SV2009003146A (es) Moduladores del metabolismo y tratamiento de los transtornos metabolicos ref. 20750-0033sv1 (137. sv1.pct)
CL2009000815A1 (es) Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria.
CA2610354A1 (en) Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
CL2022001323A1 (es) Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x
JP2020524178A5 (es)
BR112021017354A2 (pt) Método para o tratamento de doença hepática adiposa e/ou esteatoepatite
ECSP22085947A (es) Derivados de 4-(2,6-difluorofenoxi)-6-(trifluorometil)pirimidin-2-amina como potenciadores del receptor hmrgx1 para el tratamiento del dolor
BR112022008677A2 (pt) Terapia de combinação com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidina-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
CO6280474A2 (es) Composicion farmaceutica para el tratamiento de la eyaculacion precoz
PE20221568A1 (es) Compuestos de bencimidazol para el tratamiento de trastornos metabolicos
US9814731B2 (en) Method for the induction of phase 2 related genes in a mammal comprising administering exemestane
CL2020000601A1 (es) Composición farmacéutica.
KR102635938B1 (ko) 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
MX2020004667A (es) Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas.
AR066666A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
PE20121403A1 (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3
RU2011122601A (ru) Лечение синдрома беспокойных ног и нарушений сна